A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL - European Medical Journal

A Global Perspective on Emerging BTK Inhibitor Therapy Data for CLL and MCL

Not able to attend the Expert Roundtable Discussion in Paris? Access the on-demand webcast here. This interactive event features expert perspectives on current and emerging uses of BTK inhibitors for CLL and MCL. Topics include:

  • Current and Emerging Roles for BTK Inhibitors in CLL/SLL and MCL
  • Mechanisms and efficacy of currently available BTKis
  • Development of resistance and intolerance to first- and second-generation BTKis
  • Emerging reversible noncovalent BTKis
  • Selecting and Sequencing BTK Inhibitor Therapy in R/R CLL/SLL and R/R MCL
  • Case Challenges
  • Clinical Pearls and Insights of key abstracts from ESMO 2022

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.